Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39

Benzinga Newsdesk www.benzinga.com Negative 91.8%

Neg 91.8% Neu 0% Pos 0%

Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $40 to $39.